Jillian Cathcart

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung et al. · The Lancet · 2022 · 580 citations · Full text

Breast Oncology, Medicine, Clinical Trials +8

Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas

Jillian Cathcart, Ashleigh Pulkoski‐Gross, Jian Cao · Genes & Diseases · 2015 · 498 citations · Full text

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Fabrice André, Yeon Hee Park, Sung‐Bae Kim et al. · The Lancet · 2023 · 313 citations · Full text

Breast Oncology, Medicine, Clinical Trials +7

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Guy Jérusalem, Yeon Hee Park, Toshinari Yamashita et al. · Cancer Discovery · 2022 · 97 citations · Full text

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

Javier Cortés, S-B. Kim, W-P. Chung et al. · Annals of Oncology · 2021 · 96 citations

Breast Oncology, Lba1 Trastuzumab, Medicine +9